All Stories

  1. Economic and clinical benefits of early identification of acute kidney injury using a urinary biomarker

    Article • Journal of Medical Economics, July 2019, Taylor & Francis

    Dr Mark Miller

  2. Mild traumatic brain injury in the United States: demographics, brain imaging procedures, health-care utilization and costs

    Article • Brain Injury, June 2019, Taylor & Francis

    Dr Mark Miller

  3. Household Transmission of Clostridium difficile to Family Members and Domestic Pets

    Article • Infection Control and Hospital Epidemiology, August 2016, Cambridge University Press

    Dr Mark Miller

  4. Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence

    Article • Clinical Infectious Diseases, June 2016, Oxford University Press (OUP)

    Dr Mark Miller

  5. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection

    Article • Microbiome, March 2016, Springer Science + Business Media

    Dr Mark Miller

  6. Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients withClostridium difficile-associated diarrhoea

    Article • BMJ Open Gastroenterology, December 2015, BMJ

    Dr Mark Miller

  7. Usefulness of Adjunctive Fecal Calprotectin and Serum Procalcitonin in Individuals Positive for Clostridium difficile Toxin Gene by PCR Assay

    Article • Journal of Clinical Microbiology, September 2015, ASM Journals

    Dr Kristin Y Popiel, Dr Mark Miller

  8. Application of the ATLAS score for evaluating the severity of Clostridium difficile infection in teaching hospitals in Mexico

    Article • The Brazilian Journal of Infectious Diseases, July 2015, Elsevier

    Dr Mark Miller

  9. Healthcare-Associated Clostridium difficile Infections and Strain Diversity in Pediatric Hospitals in the Canadian Nosocomial Infection Surveillance Program, 2007-2011

    Article • Journal of the Pediatric Infectious Diseases Society, March 2015, Oxford University Press (OUP)

    Dr Mark Miller

  10. Evaluation of Vancomycin-Resistant Enterococci (VRE)–Associated Morbidity Following Relaxation of VRE Screening and Isolation Precautions in a Tertiary Care Hospital

    Article • Infection Control and Hospital Epidemiology, July 2014, Cambridge University Press

    Dr Mark Miller

  11. Proteomic Analysis of a NAP1 Clostridium difficile Clinical Isolate Resistant to Metronidazole

    Article • PLoS ONE, January 2014, PLOS

    Dr Mark Miller, Dr Allison McGeer, Gerald Evans

  12. Complete sequences of a novel blaNDM-1-harbouring plasmid from Providencia rettgeri and an FII-type plasmid from Klebsiella pneumoniae identified in Canada

    Article • Journal of Antimicrobial Chemotherapy, November 2013, Oxford University Press (OUP)

    Dr Mark Miller, Dr Allison McGeer

  13. Risk factors for susceptibility to varicella in newly arrived adult migrants in Canada

    Article • Epidemiology and Infection, November 2013, Cambridge University Press

    Dr Mark Miller

  14. Resolution of Clostridium difficile-Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin

    Article • Journal of Clinical Oncology, May 2013, American Society of Clinical Oncology (ASCO)

    Dr Mark Miller

  15. Polyclonal Outbreak of KPC-3-Producing Enterobacter cloacae at a Single Hospital in Montreal, Quebec, Canada

    Article • Journal of Clinical Microbiology, May 2013, ASM Journals

    Dr Louis-Patrick Haraoui, Dr Mark Miller

  16. Assessing the Need for a Medical Interpreter: Are all Questions Created Equal?

    Article • Journal of Immigrant and Minority Health, April 2013, Springer Science + Business Media

    Dr Mark Miller

  17. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy

    Article • BMC Infectious Diseases, March 2013, Springer Science + Business Media

    Dr Mark Miller

  18. Effect of Age on Treatment Outcomes inClostridium difficileInfection

    Article • Journal of the American Geriatrics Society, February 2013, Wiley

    Dr Mark Miller

  19. Characterization of a Stable, Metronidazole-Resistant Clostridium difficile Clinical Isolate

    Article • PLoS ONE, January 2013, PLOS

    Dr Mark Miller

  20. Renal Impairment and Clinical Outcomes of Clostridium difficile Infection in Two Randomized Trials

    Article • American Journal of Nephrology, January 2013, Karger Publishers

    Dr Mark Miller

  21. A lactating woman presenting with puerperal pneumococcal mastitis: a case report

    Article • Journal of Medical Case Reports, January 2013, Springer Science + Business Media

    Dr Mark Miller

  22. Carbapenem-hydrolyzing Oxacillinase-48 and Oxacillinase-181 in Canada, 2011

    Article • Emerging Infectious Diseases, January 2013, Centers for Disease Control and Prevention (CDC)

    Dr Mark Miller

  23. Renal Failure and Leukocytosis Are Predictors of a Complicated Course of Clostridium difficile Infection if Measured on Day of Diagnosis

    Article • Clinical Infectious Diseases, July 2012, Oxford University Press (OUP)

    Professor MARK H WILCOX, Dr Mark Miller

  24. Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

    Article • Clinical Infectious Diseases, July 2012, Oxford University Press (OUP)

    Dr Mark Miller

  25. Fidaxomicin Attains High Fecal Concentrations With Minimal Plasma Concentrations Following Oral Administration in Patients With Clostridium difficile Infection

    Article • Clinical Infectious Diseases, July 2012, Oxford University Press (OUP)

    Dr Mark Miller

  26. Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection

    Article • Clinical Infectious Diseases, July 2012, Oxford University Press (OUP)

    Dr Mark Miller

  27. Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

    Article • Clinical Infectious Diseases, July 2012, Oxford University Press (OUP)

    Dr Mark Miller

  28. Editorial: How Much Do PPIs Contribute to C. difficile Infections?

    Article • The American Journal of Gastroenterology, July 2012, Wolters Kluwer Health

    Dr Colin W. Howden, Dr Mark Miller

  29. Tu1073 Predictors for Treatment Failure With Fidaxomicin (FDX) and Vancomycin (VAN) in Clostridium difficile Infection (CDI)

    Article • Gastroenterology, May 2012, Elsevier

    Dr Mark Miller

  30. Divergent Rifamycin Susceptibilities of Clostridium difficile Strains in Canada and Italy and Predictive Accuracy of Rifampin Etest for Rifamycin Resistance

    Article • Journal of Clinical Microbiology, October 2011, ASM Journals

    Dr Mark Miller

  31. Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections

    Article • Clinical Infectious Diseases, August 2011, Oxford University Press (OUP)

    Dr Mark Miller

  32. Evidence of viremia in 2 cases of severe pandemic influenza A H1N1/09

    Article • Diagnostic Microbiology and Infectious Disease, June 2011, Elsevier

    Dr Mark Miller

  33. Fourteen-Genome Comparison Identifies DNA Markers for Severe-Disease-Associated Strains of Clostridium difficile

    Article • Journal of Clinical Microbiology, April 2011, ASM Journals

    Dr Mark Miller

  34. Infection prevention and control practices related to Clostridium difficile infection in Canadian acute and long-term care institutions

    Article • American Journal of Infection Control, April 2011, Elsevier

    Dr Allison McGeer, Dr Mark Miller

  35. Fidaxomicin versus Vancomycin for Clostridium difficile Infection

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 2011, New England Journal of Medicine (NEJM/MMS)

    Dr Mark Miller

  36. Randomized Clinical Trial in Clostridium difficile Infection Confirms Superiority of Fidaxomicin Over Vancomycin

    Article • Gastroenterology, July 2010, Elsevier

    Dr Mark Miller

  37. Lack of Increased Colonization with Vancomycin-Resistant Enterococci during Preferential Use of Vancomycin for Treatment during an Outbreak of Healthcare-Associated Clostridium difficile Infection

    Article • Infection Control and Hospital Epidemiology, July 2010, Cambridge University Press

    Dr Mark Miller

  38. Reply to Pillai et al

    Article • Clinical Infectious Diseases, June 2010, Oxford University Press (OUP)

    Dr Mark Miller

  39. Fidaxomicin (OPT-80) for the treatment ofClostridium difficileinfection

    Article • Expert Opinion on Pharmacotherapy, May 2010, Informa Healthcare

    Dr Mark Miller

  40. Hypervirulent Clostridium difficile Strains in Hospitalized Patients, Canada1

    Article • Emerging Infectious Diseases, April 2010, Centers for Disease Control and Prevention (CDC)

    Dr Allison McGeer, Dr Mark Miller

  41. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates

    Article • Diagnostic Microbiology and Infectious Disease, April 2010, Elsevier

    Dr Allison McGeer, Dr Mark Miller

  42. Health Care–Associated Clostridium difficile Infection in Canada: Patient Age and Infecting Strain Type Are Highly Predictive of Severe Outcome and Mortality

    Article • Clinical Infectious Diseases, January 2010, Oxford University Press (OUP)

    Dr Allison McGeer, Dr Mark Miller

  43. The fascination with probiotics for Clostridium difficile infection: Lack of evidence for prophylactic or therapeutic efficacy

    Article • Anaerobe, December 2009, Elsevier

    Dr Mark Miller

  44. O37 Molecular characterization of moxifloxacin resistance among Canadian C. difficile clinical isolates

    Article • International Journal of Antimicrobial Agents, July 2009, Elsevier

    Dr Mark Miller

  45. P63 Dynamic changes in molecular epidemiology of Clostridium difficile from inpatients at Canadian hospitals, 2005 to 2008

    Article • International Journal of Antimicrobial Agents, July 2009, Elsevier

    Dr Mark Miller

  46. 751a Opt-80 Versus Vancomycin in Clostridium difficile Infection: Results of a Randomized Clinical Trial

    Article • Gastroenterology, May 2009, Elsevier

    Dr Mark Miller

  47. Health Care–Associated Clostridium difficile Infection in Adults Admitted to Acute Care Hospitals in Canada: A Canadian Nosocomial Infection Surveillance Program Study

    Article • Clinical Infectious Diseases, March 2009, Oxford University Press (OUP)

    Dr Allison McGeer, Dr Mark Miller

  48. Infection control practices related to Clostridium difficile infection in acute care hospitals in Canada

    Article • American Journal of Infection Control, February 2009, Elsevier

    Dr Allison McGeer, Dr Mark Miller

  49. Clinical Outcomes, Safety, and Pharmacokinetics of OPT-80 in a Phase 2 Trial with Patients with Clostridium difficile Infection

    Article • Antimicrobial Agents and Chemotherapy, October 2008, ASM Journals

    Dr Mark Miller

  50. Clinical and Epidemiological Aspects of Clostridium difficile

    Article • Clinical Microbiology Newsletter, June 2008, Elsevier

    Dr Mark Miller

  51. A probiotic drink prevented diarrhoea and Clostridium difficile infection in older patients taking antibiotics

    Article • Evidence-Based Medicine, April 2008, BMJ

    Dr Mark Miller

  52. Clinical Management of Clostridium difficile-Associated Disease

    Article • Clinical Infectious Diseases, September 2007, Oxford University Press (OUP)

    Dr Mark Miller

  53. Effect of an Educational Intervention on Optimizing Antibiotic Prescribing in Long-Term Care Facilities

    Article • Journal of the American Geriatrics Society, August 2007, Wiley

    Dr Mark Miller

  54. Infection Control and the Plumber: Neonatal ICU Outbreak of Pseudomonas and Stenotrophomonas Traced to Contaminated Water Tap “Aerators”

    Article • American Journal of Infection Control, June 2006, Elsevier

    Dr Mark Miller

  55. An Outbreak of Scabies in a Long-Term Care Facility: The Role of Misdiagnosis and the Costs Associated With Control

    Article • Infection Control and Hospital Epidemiology, May 2006, Cambridge University Press

    Dr Mark Miller

  56. Enterococcus gallinarum N04-0414 Harbors a VanD-Type Vancomycin Resistance Operon and Does Not Contain a d-Alanine:d-Alanine 2 (ddl2) Gene

    Article • Antimicrobial Agents and Chemotherapy, March 2006, ASM Journals

    Dr Mark Miller

  57. P8.01 Presence of a Highly-Virulent Clone of Clostridium difficile (CD) Among Canadian Hospitals: Strain Characterization and Correlation with Severe Disease and Death

    Article • Journal of Hospital Infection, January 2006, Elsevier

    Dr Mark Miller

  58. P17.61 Surveillance for Clostridium difficile Associated Diarrhea (CDAD) Within Acute-Care Hospitals in Canada: Results of the 2005 Canadian Nosocomial Infections Surveillance Program (CNISP) Study Shows Escalating Mortality

    Article • Journal of Hospital Infection, January 2006, Elsevier

    Dr Mark Miller

  59. A Predominantly Clonal Multi-Institutional Outbreak of Clostridium difficile –Associated Diarrhea with High Morbidity and Mortality

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, December 2005, New England Journal of Medicine (NEJM/MMS)

    Dr Mark Miller

  60. Molecular and Kinetic Comparison of the Novel Extended-Spectrum β-Lactamases CTX-M-25 and CTX-M-26

    Article • Antimicrobial Agents and Chemotherapy, December 2004, ASM Journals

    Dr Mark Miller

  61. Spectrally selective UV bactericidal effect for curative treatment of post-surgical intra-abdominal abscesses and other infections

    Article • July 2004, SPIE

    Dr Mark Miller

  62. Adequacy of Early Empiric Antibiotic Treatment and Survival in Severe Sepsis: Experience from the MONARCS Trial

    Article • Clinical Infectious Diseases, January 2004, Oxford University Press (OUP)

    Dr Mark Miller

  63. Morbidity, Mortality, and Healthcare Burden of Nosocomial Clostridium Difficile-Associated Diarrhea in Canadian Hospitals

    Article • Infection Control and Hospital Epidemiology, March 2002, Cambridge University Press

    Dr Mark Miller

  64. Topical Mupirocin for Eradication of MRSA Colonization With Mupirocin-Resistant Strains

    Article • Infection Control and Hospital Epidemiology, September 2001, Cambridge University Press

    Dr Mark Miller

  65. Discordant Carbapenem Susceptibility in Methylobacterium Species and Its Application as a Method for Phenotypic Identification

    Article • Journal of Clinical Microbiology, May 2001, ASM Journals

    Dr Mark Miller

  66. Lack of Transmission of Vancomycin-Resistant Enterococci in Three Long-Term–Care Facilities

    Article • Infection Control and Hospital Epidemiology, May 1999, Cambridge University Press

    Dr Mark Miller

  67. Predictors of survival and eradication of Mycobacterium avium complex bacteremia (MAC) in AIDS patients in the Canadian Randomized MAC Treatment Trial

    Article • AIDS, April 1999, Wolters Kluwer Health

    Dr Mark Miller

  68. Group B Streptococcal Necrotizing Fasciitis and Streptococcal Toxic Shock–Like Syndrome in Adults

    Article • Archives of Internal Medicine, August 1998, American Medical Association (AMA)

    Dr Mark Miller

  69. An eye for horticulture

    Article • The Lancet, March 1998, Elsevier

    Dr Mark Miller

  70. Economic Analysis of Fluconazole versus Amphotericin B for the Treatment of Candidemia in Non-Neutropenic Patients

    Article • PharmacoEconomics, January 1998, Springer Science + Business Media

    Dr Mark Miller

  71. Determinants of Rifabutin‐Associated Uveitis in Patients Treated with Rifabutin, Clarithromycin, and Ethambutol for Mycobacterium avium Complex Bacteremia: A Multivariate Analysis

    Article • The Journal of Infectious Diseases, January 1998, Oxford University Press (OUP)

    Dr Mark Miller

  72. Epidemic Bacillus Endophthalmitis after Cataract Surgery I

    Article • Ophthalmology, November 1997, Elsevier

    Dr Mark Miller

  73. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients

    Article • European Journal of Clinical Microbiology & Infectious Diseases, May 1997, Springer Science + Business Media

    Dr Mark Miller

  74. Streptococcal Venereal Edema of the Penis

    Article • Clinical Infectious Diseases, March 1997, Oxford University Press (OUP)

    Dr Mark Miller

  75. Development of Mupirocin Resistance among Methicillin-Resistant Staphylococcus aureus after Widespread Use of Nasal Mupirocin Ointment

    Article • Infection Control and Hospital Epidemiology, December 1996, JSTOR

    Dr Mark Miller

  76. Development of Mupirocin Resistance among Methicillin-Resistant Staphylococcus aureus after Widespread Use of Nasal Mupirocin Ointment

    Article • Infection Control and Hospital Epidemiology, December 1996, Cambridge University Press

    Dr Mark Miller

  77. Gastric toxoplasmosis in acquired immunodeficiency syndrome: Antemortem diagnosis with histopathologic characterization

    Article • Gastroenterology, January 1996, Elsevier

    Dr Mark Miller

  78. Evaluation of three glutaraldehyde-based disinfectants used in endoscopy

    Article • Journal of Hospital Infection, August 1995, Elsevier

    Dr Mark Miller

  79. Anterior Chamber Contamination After Uncomplicated Phacoemulsification and Intraocular Lens Implantation

    Article • American Journal of Ophthalmology, August 1995, Elsevier

    Dr Mark Miller

  80. Uveitis and Pseudojaundice During a Regimen of Clarithromycin, Rifabutin, and Ethambutol

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, February 1994, New England Journal of Medicine (NEJM/MMS)

    Dr Mark Miller

  81. Sulfadiazine Urolithiasis during Antitoxoplasma Therapy

    Article • June 1993, Springer Science + Business Media

    Dr Mark Miller

  82. Administration of Immune Serum Globulin Following Exposure to Hepatitis C Virus

    Article • Clinical Infectious Diseases, February 1993, Oxford University Press (OUP)

    Dr Mark Miller

  83. Growth curves of Staphylococcus aureus, Candida albicans, and Moraxella osloensis in propofol and other media

    Article • Canadian Journal of Anesthesia/Journal canadien d anesthésie, May 1992, Springer Science + Business Media

    Dr Mark Miller

  84. Risk Factors for the Development of Clostridium difficile-Associated Diarrhea during a Hospital Outbreak

    Article • Infection Control and Hospital Epidemiology, June 1991, JSTOR

    Dr Mark Miller

  85. Risk Factors for the Development of Clostridium difficile-Associated Diarrhea during a Hospital Outbreak

    Article • Infection Control and Hospital Epidemiology, June 1991, Cambridge University Press

    Dr Mark Miller

  86. Tuberculosis of the skull.

    Article • American Journal of Roentgenology, November 1990, American Roentgen Ray Society

    Dr Mark Miller

  87. Antistaphylococcal activity of pentamidine.

    Article • Antimicrobial Agents and Chemotherapy, September 1990, ASM Journals

    Dr Mark Miller